The Bond Market Isn't ‘Fully Healed' From the Tariff Setback
Bond investors, on the other hand, are holding on to the wounds of the past as their losses from April's tariff shock remain. The has gained 15 out of the past 22 trading days since Trump's reciprocal tariffs were paused. The gains come despite the president's threats to place high tariffs on most countries unless they reach a deal with the U.S. While Trump has paused the harshest tariffs, a 10% levy remains on most.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Bloomberg
36 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
New York Post
36 minutes ago
- New York Post
Trump says Elon Musk will face ‘very serious consequences' if he funds Dems in future elections
WASHINGTON — President Trump warned Saturday that his former ally Elon Musk will face 'very serious consequences' if he starts bankrolling Democratic candidates for office after their nasty public split over a Republican spending bill working its way through Congress. 'If he does, he'll have to pay the consequences for that,' Trump told NBC News' Kristin Welker in an interview. 'He'll have to pay very serious consequences if he does that,' the president added. Advertisement 3 Musk and Trump have been feuding after the Tesla CEO spoke out on the president's 'big beautiful' bill. AP 'Is there anything else you just want people to know about the status,' Welker asked. 'No, not at all. We're doing great,' Trump replied. 'The bill is great. It looks like we're going to get it passed. Looks strongly like we're going to get it passed.' Advertisement 3 Musk was part of cabinet meetings during the first few months of Trump's second term. Molly Riley/White House / SWNS Musk knocked Trump during a multi-day X tirade over the debt increases contained in the 'big beautiful bill' earlier this week and said without his hundreds of millions of dollars in contributions, the president would never have been re-elected in 2024. Here is the latest on Donald Trump and Elon Musk's feud He also claimed credit for delivering the GOP a 53-47 majority in the Senate — and holding onto its majority in the House. Advertisement 3 Trump has hit back at Musk's comments in the ongoing feud. The Tesla and SpaceX billionaire contributed more than a quarter of a billion dollars to Republican candidates in the 2024 cycle, federal campaign filings show.
